$1.93
0.52%
Nasdaq, Fri, Sep 25 2026.
ISIN
US29350E1047
Symbol
RENB

Renovaro Stock price

$1.93
-0.27 12.27% 1M
-1.28 39.91% 6M
-5.12 72.64% YTD
-9.32 82.84% 1Y
-306.87 99.38% 3Y
-609.27 99.68% 5Y
-206.07 99.07% 10Y
-478.07 99.60% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.01 0.52%
ISIN
US29350E1047
Symbol
RENB
Industry

Is Renovaro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$4.4m
Cash
$1.6m
Shares outstanding
162.4m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
80.9%
Return on Equity
-61.4%
ROCE
-21.9%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-19.3m
EBIT
$-19.4m
Net Income
$-67.3m
Free Cash Flow
$-8.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
19.5%
EBIT
19.4%
Net Income
23.5%
Free Cash Flow
21.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.1
Short interest
0.6%
Employees
25
Rev per Employee
$0.0

Financial data from Renovaro

Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
11% 11%
-
- Research and Development Expense 0.89 0.89
73% 73%
-
-19 -19
20% 20%
-
- Depreciation and Amortization 0.13 0.13
8% 8%
-
EBIT (Operating Income) EBIT -19 -19
19% 19%
-
Net Profit -67 -67
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Renovaro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Head office United States
CEO Mr. Weinstein
Employees 25
Founded 2011
Website renovarobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today